FDA approves Intra-Cellullar's schizophrenia drug, shares soar 85%

FDA approves Intra-Cellullar's schizophrenia drug, shares soar 85%
Reuters: Health
Intra-Cellular Therapies Inc said on Monday its lead drug to treat schizophrenia in adults has received approval from the U.S. Food and Drug Administration, sending its shares soaring 85%.